Market Movers, June.03

Genocea Biosciences, Inc. up 97.86% in the premarket on 2,286,223 traded after announcing: Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8+ T cell responses to 53% of vaccine neoantigensRead more

Infineon to acquire Cypress, up 25%, 12,016,054 shares traded. Infineon to pay US$23.85 per Cypress share, equivalent to a total enterprise value of €9.0 billion….Read more

Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM, up 25% on 823,839 shares traded, 20 minutes to open…Read more

 Avenue Therapeutics, Inc. (NASDAQ: ATXI)  announced that its second pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 24 hours (SPID24) compared to placebo in patients with postoperative pain following abdominoplasty surgery. In addition, the trial met all of its key secondary endpoints. Up 18.08% on 12,123 shares trade, 20 minutes to open…..Read more

 MGDS announced the signing of a $3,000,000 agreement with Golden Grand for the know-how licensing and sale of goods for Medigus Ultrasonic Surgical Endostapler (MUSE™) system in China, Hong Kong, Taiwan and Macao.Golden Grand (Shanghai Golden Grand-Medical Instruments Ltd.) has been Medigus’s distributor of the Ultrasonic Surgical Endostapler (MUSE™) systems in China since 2015. Up 12.24% on 54 000 shares …Read more

June 01, 2019 Celldex Therapeutics, Inc. (NASDAQ:CLDX), up 6.91% on 33540 shares traded, presented results from the CDX-3379 clinical program at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. To date, three studies of CDX-3379 have enrolled patients with head and neck squamous cell carcinoma (HNSCC), including the ongoing Phase 2 exploratory study of CDX-3379 in combination with Erbitux®  (cetuximab) in patients with cetuximab-resistant, advanced human papillomavirus (HPV) negative HNSCC who have previously been treated with an anti-PD1 checkpoint inhibitor. Read more

10:57 Dow up +87.22 (+0.35%); Volume 66,509,468

“Mirati Therapeutics (MRTX +32.4%) is up on over 40% higher volume in apparent response to Phase 1 data on Amgen’s KRASG12C inhibitor AMG 510 presented at ASCO in Chicago”, according to Douglas House of SeekingAlpha

Tech stocks get crushed today.

Leave a Reply